What is Multiply Labs?
Multiply Labs specializes in the development of advanced robotic systems tailored for the manufacturing of precision medicines. By integrating sophisticated automation into the cell therapy production workflow, the company enables life sciences organizations to achieve industrial-scale output without sacrificing the flexibility required for personalized treatments. Their technology is designed to bridge the gap between laboratory-scale research and commercial-scale manufacturing, effectively lowering the barriers to entry for next-generation therapies. As the demand for gene-modified treatments continues to rise, Multiply Labs serves as a vital partner for biotech firms seeking to optimize their manufacturing processes and improve patient access to life-saving medical innovations.
How much funding has Multiply Labs raised?
Multiply Labs has raised a total of $22.8M across 2 funding rounds:
Private Equity
$2.8M
Series A
$20M
Private Equity (2016): $2.8M with participation from CRCM Ventures, P101, Fenox Venture Capital, and Graph Ventures
Series A (2021): $20M led by Fifty Years, Casdin Capital, Founders Fund, Lux Capital, Pathfinder International, and Garage Capital Ventures
Key Investors in Multiply Labs
Founders Fund
Founders Fund invests in the world's most important and valuable companies across all geographies, sectors and stages, providing maximum support with minimum interference.
Lux Capital
Lux Capital is a venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, including robotics and biotechnology.
Casdin Capital
Casdin Capital brings deep expertise and a long-term perspective to financing the next generation of life science innovation, with a focus on diagnostics and molecular information.
What's next for Multiply Labs?
Looking ahead, the strategic deployment of the $20M will likely focus on expanding the company's operational footprint and enhancing its robotic platform's capabilities. As Multiply Labs moves deeper into the enterprise-level market, the focus will shift toward scaling production capacity and forging deeper partnerships with global pharmaceutical leaders. The company is poised to capitalize on the increasing shift toward decentralized and automated manufacturing, potentially setting a new benchmark for efficiency in the life sciences industry. By leveraging its robust investor base, the firm is well-positioned to navigate the complexities of regulatory compliance and global supply chain integration, ultimately driving the next wave of innovation in precision medicine.
See full Multiply Labs company page
